๐ŸŽ Black Friday: 50% off Unlimited and 30% off Pro annual plans
The Pennant Group, Inc. (PNTG)
NASDAQ: PNTG ยท Real-Time Price ยท USD
34.64
+0.55 (1.61%)
Nov 20, 2026, 4:00 PM EST - Market closed
โ† View all transcripts

2026 Stephens Annual Investment Conference | NASH2026

Nov 17, 2026

Summary

2026 combined large-scale integration, same-store growth and expanded leadership capacity. For 2027, priorities include acquired-asset optimization, renewed home health and hospice M&A, and occupancy gains; long-term margin targets are 18% for home health and hospice and 15% for senior living.

Raj Kumar
Analyst, Stephens

All right. Thanks, everyone, for joining us. We are going to move on to our next panel here with The Pennant Group, a leading provider of home health and hospice services and an operator of senior living facilities across the country. Joining us from Pennant today are John Gochnour, President and COO, and Lynette Walbom, CFO. I want to thank both of you for joining us here today at our conference, and if it is all right with you, I think we will just jump right into Q&A.

John Gochnour
President and COO, The Pennant Group

That sounds perfect. Thank you, Raj.

Raj Kumar
Analyst, Stephens

Awesome. All right. Maybe to kick off the conversation, it would be helpful to go through a walk-through, a year in review, maybe highlighting some of the key operational milestones or results, and maybe just framing how 2026 has played out relative to kind of internal expectations.

John Gochnour
President and COO, The Pennant Group

Yeah. 2026 has been a remarkable year for us at The Pennant Group. There has been a tremendous amount of growth, both acquisitional growth, and we will talk about that a little bit, but also from the organic same-store side. I think when you look at the highlights, there has been an element of being able to integrate the large transaction that we did with UNH, where we purchased assets from Amedisys and LHC, and being able to integrate that over the course of the year. Then to follow that up with, at our same-store operations, being able to drive that same-store growth as we elevated leaders. I think that is the second thing, is we saw an investment in leadership. We have hired more than 100 CITs, CEOs in training, this year, which really sets us up for the next phase of our growth.

And then we have also invested from a service center standpoint, adding investments to our finance team, to our payer strategy team, to our IT team, as we have deepened the bench in preparation for future growth. Really a year of intense growth. The other thing I would call out is, in senior living, where over the last two years, we have done 16 acquisitions. We have done seven this year. Intensive growth, record performance, bumps and bruises along the way, as is common when you are growing at a rapid pace. But overall, it has been a great year.

Raj Kumar
Analyst, Stephens

Got it. You touched on the local operating model. It is a key core tenet of The Pennant Group model. As we kind of think about the service center, you alluded to this a little bit in your opening comments, but maybe what capabilities do you kind of foresee still needing more investment in as you kind of maybe think about operating leadership, clinical leadership, payer strategy, I guess, technology compliance. Maybe what are some of the nodes that you think are still maybe need updating as we kind of think about the next phase of growth?

Lynette Walbom
CFO, The Pennant Group

I think when you look at the service center, our main goal in the service center is to accelerate the results of the field. I think over the last two years, we have had the opportunity to grow the service center as we have had these acquisitions that we have brought on. We have put a lot of leaders in place across all of those different functions that you called out. I think as we look to where we will continue to add additional resources in the service center is really what are the things that we can do to take advantage of AI, whether it is from a clinical perspective and helping on documentation. That is a piece that I think that we will continue to push on.

Also making sure that from a clinical perspective, that we continue to be able to drive the clinical quality that we want to have, because I think that is really a key factor in being successful in our local operations, is having that clinical piece.

Raj Kumar
Analyst, Stephens

Got it. Without local leaders, that is core growth of the formula. You talked about the CEO-in-Training program. As we kind of think about maybe dispersion across the portfolio and performance, clearly, you are overtaking assets that are distressed, that take time to kind of overcome. As you kind of think about the dispersion around just local level operations, what are you kind of seeing, and how does that gap between operating performance contract over time as those new CEOs kind of become more encompassed in the cluster model that you guys have built out?

John Gochnour
President and COO, The Pennant Group

Well, Raj, ours is a people business. At the end of the day, what we do is we help people deliver care to people. There is going to be some variability in operations, but there is also, we have been doing this for a long time, right? Over the last 15 years, we have developed a more and more refined playbook, a more and more sort of refined recipe for if you do these things, then you will find success, right? That encompasses everything from the way we deliver care, right? How we measure productivity, how we hold people accountable to standards, how we create alignment with them by rewarding them when they are productive and effective at their jobs, to the back office. How do we collect and make sure that our DSO is very low, that our collections are very strong?

The first thing about that, I think, is taking the lessons that we learn and constantly iterating sort of the playbook or the recipe that allows a new leader coming from the outside to go through our CEO-in-Training program and step into an operation with a high probability of success. Because ultimately, that is the way we measure our success. How good are we at developing leaders and putting them into opportunities, giving them the chance to grow and create a million dollars worth of value, become a CEO?

I think the second piece of that is, even as we grow, and you saw this demonstrated over the last two years, we did Signature, which was acquiring 13, a multi-site acquisition across the Pacific Northwest, our partnership with Hartford HealthCare, where we became the largest provider in Connecticut, and then the assets we did in the Southeast, where we acquired 50 locations. In each of those, we had to implement our cluster model with new leaders, many of whom remained in place from the prior organization. So, we took those leaders through our training program, but we also supported them with clusters that understood our model and understood how to create accountability and ownership in our model. I think the results that you see right now, the year-over-year results, they demonstrate sort of the power of that model to help support individual operations.

As we grow, as we continue to deepen our bench of leadership talent, as we continue to refine the playbook, there is this opportunity to create less dispersion among the individual results of operations, and in doing so, to enhance the overall profile from a margin standpoint, from a clinical outcome standpoint, ultimately from a growth standpoint of the whole portfolio.

Raj Kumar
Analyst, Stephens

Got it. Maybe just doing some table setting for 2027. I know you guys have not given out formal guidance, but as we kind of think about some of the puts and takes, maybe what should investors keep top of mind? Maybe just remind us of your kind of normalized long-term earnings algorithm as we kind of comp against a hefty M&A with the AMED UNH assets and as we kind of think about 2027.

Lynette Walbom
CFO, The Pennant Group

Yeah, I think when we look at 2027, I think one of the biggest things is we have done the full transition for the AMED and LHC assets. So, it is really how can we get them to the margin where we are currently operating at on our home health and hospice side of the business, which is about 16%. What are those things that we can do and pull, those levers that we can pull? That will be a big piece. I think as we look at it as well, it is being able to take the acquisitions, the seven acquisitions that we did in 2026 for senior living and some of the late in the year 2025 acquisitions. How do we increase occupancy and driving occupancy in those?

When we are talking about our long-term margin targets, on the senior living side of the business, we believe that we can get our operating margin to a target margin of 15%. A lot of that is driven by occupancy, and so as we bring in some of those more distressed, when it comes to occupancy, senior living communities, that will pull on that. But driving to that margin. On the home health and hospice front, currently at about a 16% margin, trying to push towards an 18% long-term margin target.

Raj Kumar
Analyst, Stephens

Got it. CMS recently extended the moratorium, although there was nuances around providing benefits for existing Medicare licensed providers. As we kind of think about, you always are looking to kind of replenish the M&A pipeline. As we kind of think about maybe any impacts from that, curious on if that kind of changes any plans for 2027 around M&A.

John Gochnour
President and COO, The Pennant Group

Yeah, it doesn't, in part because the moratorium is specifically for de novo or new license enrollments. Because of that, we're able to still pursue our acquisition targets and our acquisition strategy with the same level of intensity as we were planning. You saw in 2026, really on the home health and hospice, we haven't done acquisitions because of the integration efforts in Tennessee, Alabama, Georgia, and then continuing what we were building in Connecticut. I do think in 2027, you're going to see that come roaring back to life. We have a strong pipeline of transactions, of potential transactions that we've been cultivating over time, and that I think is going to create some unique opportunities in 2027.

As far as the impacts of the moratorium, we were really pleased with the changes they made, in part because it allows us to do new branch certifications and service area expansions. A lot of our growth is local CEOs saying, "Hey, in this community next door, there's not providers who are high quality, and I think we could win if we went into that." That's going to facilitate more of that, which allows us, again, it's just another lever that we can pull and have pulled historically to drive growth, that we weren't able to pull over the last six months because of the moratorium. There will still be a couple of de novos that we won't be able to do because they're distant from our other operations, and we had planned to do them because we saw opportunity there.

That's sort of the puts and takes of the government's efforts to combat fraud, waste, and abuse in the industry. In many ways, we are emerging stronger because of our strong clinical teams, because of our technology investments, because of our ability to react and respond to that difficult regulatory environment. There's obviously a take here too in not being able to do de novos.

Raj Kumar
Analyst, Stephens

Got it. Maybe just kind of going into or diving deeper into the home health business. Clearly, 3Q same store home health admissions, 8%, including 12% growth in Medicare admissions. That is all against the backdrop of a negative rate environment where the economics on a per episode basis have been dwindling over the last couple years as CMS has implemented rate cuts. As we kind of think about just your organic growth, how much of admission growth is maybe reflective of market share gains, or general referral source penetration, improved clinical quality, or just showcasing to payers, "Hey, that we have the strongest clinical outcomes"?

John Gochnour
President and COO, The Pennant Group

Yeah. I think there is a couple of different things at play here. First, we do have a demographic tailwind, and that is meaningful, and I think it will be meaningful in years to come, even more meaningful as the baby boomer generation ages. I think that would not drive anywhere near 8% total growth or 12% Medicare growth. What really that comes back to is a couple things. One is the ability to attract and retain talent. Ultimately, as the population ages, it is less about the volume and more about can you serve the volume. Where we are the employer of choice, we are often the provider of choice because we can meet the needs of our referral sources.

The first reason I think we have been able to take market share is because of our ability, our focus on culture, our ability to create environments where employees want to work, and therefore our ability to take more volume. The second piece is, our whole model is based on this idea that healthcare is local, and I think that proves out in the form of every referral source in a different community has different needs, and our local operators are the decision makers. They are positioned with the resources they need in order to develop unique clinical programs, to develop fast and easy referral responsiveness. In doing that, I think we have been able to position ourselves to take market share, especially in this unique regulatory environment where people are struggling.

It has given us a chance to kind of not pick and choose between referrals, but in some cases, you are balancing between you have got a bunch of managed care referrals, you got Medicare referrals, what do you take? When you are in the position to choose, that is a better position to be in. Yeah. I think that is a big part of it. When you look at the payer piece, I think that is one of the things Lynette highlighted in calling out our investment in payer strategy, and I think over the next couple years, already about 47% of our managed care contracts are episodic. When you look at our portfolio of, we have Medicare episodic, we have about 47% of our managed care volume is episodic, and so the opportunity exists to take the remaining 50% of that managed care volume and transform that.

We'd like to transform it into episodic contracts because we believe we can deliver better care more efficiently in those volumes. I think that's another piece that will drive that organic growth.

Raj Kumar
Analyst, Stephens

Got it. Then maybe double-clicking on that, are those episodic arrangements with payers, are those kind of in the sense that you're guaranteeing labor capacity for patients, or is it more so that it's just clinical outcomes-based and they're kind of maybe helping close the gap between fee-for-service?

John Gochnour
President and COO, The Pennant Group

Yeah. We don't ever guarantee volume, and that's something that we've determined because of our locally driven model, our operators know exactly what they receive in reimbursement for a particular patient, and they have to be able to make those decisions based on what their business can afford in order to be self-sufficient. We don't guarantee volume, but I do think we offer payers a unique product. We've got some of the best clinical outcomes in the industry, especially on rehospitalization. So when you're a payer focused on total cost of care, we have something unique to offer. I think now our geographic sort of dispersion has given us something unique to offer, where we can offer coast-to-coast coverage, particularly in heavy utilized states like Tennessee. I think we've got a lot that's allowed us to push on payers and negotiate with a little more leverage.

I'm excited to see over the next couple years, I think you'll see us being willing to take a little more risk, and you'll see us pushing hard from a rate standpoint. Those represent potential upsides to our performance.

Raj Kumar
Analyst, Stephens

Got it. Maybe just on the Amedisys LHCG branches, clearly, I think the margin profile shifts to single digits relative to the 16% that your mature agencies operate at. As we think about this nine-quarter timeframe in terms of integration that you guys have laid out, I guess, do we start run rating towards 16% as we exit 2027 for those assets, or is it more of a longer tail to that?

John Gochnour
President and COO, The Pennant Group

We view optimization, we've been doing this for 15 years, and generally it takes about nine quarters to get fully optimized. Here, we've owned these assets for a year, but that entire year has been dedicated to transition. We're starting to optimize now, and I think that over the next nine quarters, you're going to see a significant step forward in 2027, but I think we're going to fully realize that in 2028.

Raj Kumar
Analyst, Stephens

Okay. Got it. I guess, you talked about the EMR conversion that affected maybe half of the acquired patient population. I guess, how quickly should census and clinical productivity normalize from post the EMR conversion?

John Gochnour
President and COO, The Pennant Group

The way that we build our performance is we expect anywhere from a 5% to 10% census disruption when we go through an EMR transition. You're pulling all these clinicians out of the field, you're asking them to spend hours and hours doing training. You usually undergo some turnover because people don't want to go through that transition in systems. That's just what we pro forma. This transition has been better than that. We've emerged a little bit ahead of where we would expect. I think that probably means that we're going to be able to recover and get towards optimization quickly. I would expect, we saw some census disruption in the third quarter between August 1st and October 31st. We had about 50, a little over 50% of the employees and the patient population were transitioned.

Coming out of that, I would expect that we're going to be, people are able to breathe a sigh of relief. They're able to now focus on, "I'm here, I've got the full technology stack, I have full visibility, expectations are clear, and let's go." We're excited to see sort of the census grow well beyond where it is now, and the kind of inherent upside of operating in these new states, now that we're fully transitioned.

Raj Kumar
Analyst, Stephens

Great. I guess, we've talked about this, quality outcomes, clearly that's the kind of important driver. I guess kind of if we're kind of bridge it in terms of where that benefit shows up first, is it kind of on the referral side, and then how soon after does that show up on, say, the reimbursement front when payers are looking to work with quality providers?

John Gochnour
President and COO, The Pennant Group

Yeah. I think it's already shown up. If we're using Tennessee as an example, right, we took over operations of the sort of some of the premier names in our industry in Amedisys and LHC. So, they have negotiated contracts over 20 and 30 years with these payers, and I think coming in and being able to say, "We're going to deliver a higher quality product, or at least as good a product," that allowed us to make sure that we were able to transition those contracts onto our paper at the same or better rates. I think that was the first evidence of the fact that quality outcomes are going to factor in there.

I think what you'll see over the future is us being able to take the density and volume we have in Tennessee and go back and leverage that to say, "Quality outcomes plus density and the ability to serve the entire state, let's push even harder on rate." So, I do think that's really how it plays out. The other thing I would say, you call it out, Raj, about the referral volume, and I think that's always a question that referral sources are asking is, "How good are you?" That's a two-part analysis. One is, "How good of a quality outcome are you going to get?" Because I want my patient to be happy. I want them to come back to use my service if they need to return to the hospital, they need to return to the physician.

But it's also about how responsive are you? How quick are you? How communicative are you? And that's where I think our technology systems and processes really thrive and drive value, is in being very responsive to those local referral sources, being fast and easy to work with, and that's what's driven our volume growth in both home health and hospice, and I think it's what will help us drive in Tennessee.

Raj Kumar
Analyst, Stephens

Got it. Maybe just one last one on home health. On the regulatory front, I think the RCD expansion in California kind of hitting next year. As you kind of think about your prior experience in Texas, could you illustrate kind of from your results, how you've had kind of experience with kind of claims processing, and maybe helping us kind of ring-fence any potential impacts from kind of the initial implementation of that program in California?

John Gochnour
President and COO, The Pennant Group

Yeah. RCD was kind of a mess in Texas, in part because the MAC didn't really know. They were implementing it for the first time, and I think once we worked through the messiness of it and determined, "Hey, here's exactly how you meet the requirements," our Texas company has continued to be one of our lowest DSO companies, despite RCD. And so, I think with California, it's a different MAC. I would expect some messiness initially, just because the MACs, NGS is a different MAC than Palmetto, and they've got to figure out exactly how to implement RCD.

But I think over time, this is another area where having a sophisticated service center who's been through this in multiple jurisdictions, we have people on our team who went through RCD in Ohio, we have them from Texas, and so we're going to be able to bring that to bear in supporting our California operations. And I expect messiness in the beginning, but in the long term, I don't expect it to have a material impact.

Raj Kumar
Analyst, Stephens

Got it. Just on hospice now, clearly same store ADC up double digits in the third quarter, materially ahead of just kind of admissions growth, which is kind of low single digits. As you kind of interpret that relationship between ADC and admissions growth, how should we kind of think about where we are in terms of the recovery post-pandemic and kind of length of stay, patient mix, and referral mix?

John Gochnour
President and COO, The Pennant Group

Yeah. Our length of stay ticked up this quarter, which we were grateful to see. We are back. We, for the first time since the pandemic, hit 100 days. Obviously, that is discharge length of stay, not median length of stay. We were really pleased to see that. We still feel like that is, we are still 10% below where we were pre-pandemic. There is still opportunity to reach patients earlier, get them into the benefit of hospice earlier, and I think continue to grow length of stay. As far as the kind of relationship or interaction between length of stay and admissions, there is an important sort of element here, and it comes back to staffing. The ability, so if your ADC is growing by 13%, that means you got 13% more patients that you are serving, which means less time to go and do new admissions.

It is not a direct correlation because other factors come into play, like length of stay. We were pleased with the admission growth and that we were being chosen more and more, but we were really pleased with ADC growth and to see that LOS tick up a little bit.

Raj Kumar
Analyst, Stephens

Got it. Maybe just kind of on the referral piece, during the pandemic, we saw a flip where SNF-related patients or SNF discharge patients were coming into hospice who exhibit a lower length of stay than, say, the acute care setting. Or no, vice versa. Let me flip that, I think, the logic. Has that normalized as we kind of think about the referral mix? On the kind of the getting the hospice benefits sooner, is it more just an educational component?

John Gochnour
President and COO, The Pennant Group

Yeah. On the first one, it hasn't normalized for us, but our data is a little bit skewed by the fact that since the pandemic, we've entered four joint venture relationships with health systems that mean we're inherently, we have a lot more hospital-driven referrals that are being driven there. It's a little bit tricky to parse out that data and determine on the core business that we had pre-pandemic, is it the same amount? Is it less? The data would say it's a little bit less still, that we're still Which is good because it means we improved our relationships with health systems, with SNFs, and we maybe have a little bit less out- But the other thing that I would highlight is, for example, in Connecticut right now, we have moved the length of stay significantly, and it's still at 40 days.

That is in part due to, in that part of the country, the Northeast, we just see there's less awareness of the opportunity that families have to choose hospice. In the Southeast, I think it's very well-known, it's very well-established. You see a more traditional length of stay. But in the Northeast, we've got a lot of opportunity there to push on it. So, it is an education component, it is an awareness component. People are eligible many times for a long time before they actually elect. Sometimes they have to go to the hospital, have a significant healthcare adverse event, and then elect right before they die. That's unfortunate because they really miss out on the ability to stay at home, the ability to be comfortable and have their symptoms managed through that last phase of their life, which is what we really want to encourage.

Lynette Walbom
CFO, The Pennant Group

I think with us operating on the home health side and really paying attention to when we can appropriately bridge patients from home health to hospice is also another thing that we are really driving through technology to make sure that where we can, early education and helping with that bridging is something that we're really pushing on as well.

Raj Kumar
Analyst, Stephens

Yeah, that's a great example. I think as you kind of think about the bridging opportunity between just kind of your own home health patients over to hospice, kind of where does that stand today, and where do you kind of see the long-term opportunities as you kind of think about the percentage of overall patients that you serve in the hospice book?

Lynette Walbom
CFO, The Pennant Group

I think that it's one that we can still improve on. When we look at that piece, I think as we are better about educating earlier and helping those families recognize what that benefit is and how they as a family and also the patient can benefit from that will continue to drive better bridging in that process. When you look at it as across all of the services that we offer, that bridging from, we have a home care line of business into assisted living. When can we use assisted living, in the assisted living use our home health and hospice?

I think those are all levers that we are continuing to push onto how can we really make sure that we're taking care of that patient from the beginning of them being able to receive services through home care all the way through the end of life.

John Gochnour
President and COO, The Pennant Group

It's another area where our innovation has been focused. Internally, when we have seen gaps in what's available in the market, we have a team of internal developers, and one of the areas they've focused on is this continuum of care, being able to get the patient to the right place in the right setting to receive the right care at the right time. That's one of our sort of overall mantras as an organization. We're risk stratifying patients early on so we can identify when symptoms start to present that would make them eligible, so we can have that conversation with them earlier in the process. Doesn't mean that they're necessarily ready to elect, but the more awareness that exists, the better opportunity to get them to the right place on the continuum at the right time.

Raj Kumar
Analyst, Stephens

Got it. Then kind of looking at senior living now, clearly very acquisitive since 2025, and from an expansion standpoint, kind of saw some volatility in occupancy as we kind of think about the expansion cohort. How should we kind of be thinking about the pace and the trajectory of those newly acquired senior living communities, and also from a margin perspective, kind of getting those back into the normal transition cadence that you kind of typically outlined, like that nine-quarter kind of optimization?

Lynette Walbom
CFO, The Pennant Group

Well, I still think that nine-quarter optimization is accurate as we're looking at them. Some of those levers are easier to pull when it's a senior living community that we've gone into that has higher occupancy, but maybe they have some cost control measures or using a lot of agency. We can come in, implement our model, and really drive down those agency costs as we get the right leaders in place. That helps us to be able to turn those ones. I think we talked about one of them, Harvest Home, in our earnings call just recently, and how we were able to transition that one. It was acquired in 2025, and the performance improvements that we've had there.

That was probably one of those that was more in that, not lower occupancy, but lower than our optimal occupancy, but we were able to drive occupancy and have those cost measures take place, and it's been a winner for us. I think as we look at some of those other acquisitions that we've done that have been more significantly distressed in occupancy, at that 50% or below occupancy, some of those will take longer to turn. But when we look at how we do that, it's really making sure we get the right leaders in place, not just from an executive director perspective, but having the right clinical partner, the right family advisor to help drive the residents to close, and they're good at closing on those leads. I think those are the things that will really drive the occupancy front, but still looking at that nine quarters.

Raj Kumar
Analyst, Stephens

Got it. With senior living, there's clearly a private pay dynamic there, and as we kind of think about the macro backdrop, one of your senior living peers have called out some potential deferral into senior living and maybe creating a pent-up demand type of dynamic. As I kind of think about rates, clearly that's been a strong suit for the industry, where you've been able to pass up down rates more meaningfully. How should we kind of think about the balance as you kind of think about 2027 pricing, the kind of the balance between rate and kind of looking to expand occupancy?

Lynette Walbom
CFO, The Pennant Group

Yeah, I think that we will continue to be able to drive rate in that mid-single digit . When we look at the communities that we're in and I think that would be between both on the actual room and board side, we can drive that rate, and then also making sure that we're adequately charging for cares and assessing the cares of those residents and what their needs are and making sure that we're adequately doing that. I think those two components will really allow us to continue to drive rate in that mid-single digits range.

Raj Kumar
Analyst, Stephens

Got it. As we kind of think about The Pennant Group Senior Living business, there's the component of Medicaid waivers and filling those beds with those residents. As we kind of think about maybe the midterms and the implications around that, do you think that's still a strength for the business, and do you see more authorizations coming into any given state, or fortifying existing authorizations to continue to fill those beds with Medicaid residents?

Lynette Walbom
CFO, The Pennant Group

I think that's still an opportunity for us as we're in some of the states that we're in. Obviously, Medicaid rates across states vary. When we look at Arizona, California, some of those other states, we still see it as a good opportunity for us to continue to expand that Medicaid population. We've been a solution, and we've worked well with the state in making sure that we're a partner that can take those residents and provide great care and essentially lower the cost for them as they're receiving a safe place to be and not going into a higher acuity setting because they don't have anywhere else to go.

Raj Kumar
Analyst, Stephens

Got it. As we kind of wrap up here, as we come up on time, Johnny, you might be surprised I didn't ask you for a home health reimbursement question, right? We're in a good year. I guess as we kind of think about generally The Pennant Group story around acquisition execution, increasing the leadership capacity pipeline, and just now optimizing the acquired businesses, what do you believe the market most underappreciates about The Pennant Group story today and the earnings power potential over the next, say, three to five years?

John Gochnour
President and COO, The Pennant Group

Yeah. I think there's a couple of things. One of them, I think, is related to home health and hospice, and that is just we have developed muscles that we didn't have as an organization over the last three years. The ability to transition these larger opportunities, first of all, to find opportunities that still fit our disciplined acquisition profile and get them at prices that we viewed as opportunistic, but then also to be able to take them and transition them while also continuing to improve and drive same-store results. We've had multiple quarters this year where we've seen same-store margin improve despite the fact that the overall margin is being brought down by these new acquisitions that have a ton of upside. I think that's one thing that is just kind of to someone who's just watching from the outside, they may not be seeing that.

The second piece is we really believe that we have got a bright future in senior living, and that it is an underappreciated part of our portfolio. That here, we have a legacy of strong communities with low rents, with the ability to move margin, and obviously, there is a short-term blip when we have a number of acquisitions in this quarter. But when you look at the long-term upside, the demographic trends that are so favorable and the demand for senior living that is inherent when our generation, I think, is much more comfortable with senior living as a potential solution than previous generations might have been. I think that there is just a lot of opportunity there to unlock.

That is the two things I would highlight, is just the way the organization has changed, particularly on the home health and hospice side, the ability to do larger transactions, to integrate them effectively into The Pennant Group model, and change them dynamically to produce better results. Then two, just that there is a real opportunity in senior living, and that is a part of our story too.

Raj Kumar
Analyst, Stephens

Great. I think that puts us at time. John, Lynette, thank you for joining us today.

John Gochnour
President and COO, The Pennant Group

Thank you.

Lynette Walbom
CFO, The Pennant Group

Thank you.

John Gochnour
President and COO, The Pennant Group

Appreciate it.